OBJECTIVES: With availability of biologic agents, remission is a realistic goal for many rheumatoid arthritis (RA) patients. We characterized patterns of disease activity among patients receiving TNF-inhibitors (TNFi) according to disease activity at TNFi treatment initiation. METHODS: Within the Corrona registry we identified RA patients previously treated with ≥1 conventional synthetic DMARD who initiated their first TNFi and had at least 1 year of follow-up.  We excluded patients with age of RA onset <18, comorbid psoriasis/psoriatic arthritis, fibromyalgia or osteoarthritis.  Disease activity was assessed using Clinical Disease Activity Index (CDAI) while on TNFi therapy.  We examined the lowest level of disease activity across all visits through 1-year while on TNFi therapy. RESULTS: CONCLUSIONS: Many biologic naïve RA patients initiating their TNFi in M/HDA failed to achieve remission or LDA during 1-year period while remaining on TNFi therapy.  Half of these patients remained on the initial TNFi.  Further investigation is needed to examine whether this is due to a lack of treat to target approach to care or barriers to aggressively manage patients.